Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive Disorder

Rickels, Karl; Αθανασίου, Μαρία; Robinson, Donald S.; Gibertini, Michael; Whalen, Heidi; Reed, Christopher Robert

doi:10.4088/jcp.08m04637

Cited by 134 publications

(160 citation statements)

References 0 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…41 Two placebo-controlled studies and one long-term tolerability and safety trial found no SD associated with this compound. [42][43][44] As in other studies, both the treated and placebo groups experienced increased sexual function with no difference between the groups, suggesting a placebo effect on sexual function.…”

Section: Feature Articlesupporting

confidence: 51%

Antidepressant-Induced Sexual Side Effects: Incidence, Assessment, Clinical Implications, and Management

Francois¹,

Levin²,

Kutscher³

et al. 2017

Psychiatric Annals

View full text Add to dashboard Cite

show abstract

Section: Feature Articlesupporting

confidence: 51%

Antidepressant-Induced Sexual Side Effects: Incidence, Assessment, Clinical Implications, and Management

Francois¹,

Levin²,

Kutscher³

et al. 2017

Psychiatric Annals

View full text Add to dashboard Cite

show abstract

“…Diarrhea, nausea, and somnolence were the greatest side effects noted [Khan et al 2011]. There were clinically no significant differences for men or women in regards to sexual dysfunction outcome measures [Rickels et al 2009]. Vilazodone efficacy in MDD was further established in two 8-week, multicenter, randomized, double-blind, placebo-controlled studies in adult (1870 years of age) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) [APA, 2000] criteria for MDD.…”

Section: Clinical Studiesmentioning

confidence: 99%

Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor

Schwartz

Siddiqui

Stahl

2011

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Abstract:Background: Vilazodone is the latest US Food and Drug Administration approved antidepressant agent available in the USA. Its putative mechanism of antidepressant action enhances the release of serotonin across the brain's serotonergic pathways specifically by inhibiting the serotonin transporter, similar to a selective serotonin reuptake inhibitor (SSRI), and simultaneously stimulating serotonin-1a receptors via partial agonism, similar to the anxiolytic buspirone. This combined activity in the single vilazodone agent has been termed by the authors as being a serotonin partial agonist and reuptake inhibitor or (SPARI). Methods: A MEDLINE and Internet search was conducted and the resultant preclinical and clinical evidence was reviewed. The authors attempt to review laboratory data, animal model data and human trial data to develop a translational theory on the mechanism of antidepressant action of this agent and also its adverse effect potential. Results: Randomized, controlled empirical data for vilazodone have gained it approval for treating major depressive disorder. It combines two well known pharmacodynamic mechanisms of serotonergic action into a novel agent. Although no head-to-head studies against other antidepressants have been published, the efficacy data for vilazodone appear comparable to other known antidepressants, with similar gastrointestinal side effects to SSRI or serotonin norepinephrine reuptake inhibitor (SNRI) antidepressants, but possibly with a lower incidence of sexual side effects and weight gain. Discussion: Vilazodone will lend itself to the current armamentarium in the treatment of major depressive disorder and may hold promise for patients who cannot tolerate other antidepressants. Its unique SPARI mechanism of action could also be efficacious for patients who do not respond to SSRI or SNRI antidepressant monotherapies.

show abstract

“…The safety profile and tolerability of vilazodone is comparable to other SSRIs and its main side effects include diarrhea, nausea, and headache [28]. It has less incidence of sexual side effects.…”

Section: Discussionmentioning

confidence: 71%

Vilazodone for the Treatment of Paternal Post Natal Depression

Khouzam¹

2017

Clin Depress

View full text Add to dashboard Cite

Maternal postpartum depression is well recognized by clinicians as one of the psychiatric complication of delivery, conversely paternal postpartum depression or paternal postnatal depression which affects up to 10% -14% of new fathers 6 to 12 months after a child birth is rarely recognized and treated. Without proper diagnosis and prompt treatment paternal postnatal depression could lead to dire consequences including, deterioration in paternal mental health, loss of paternal bonding with the newborn child, which has been associated with long term later child psychiatric complications such as conduct disorders, hyperactivity, anxiety, depression, posttraumatic stress disorder and delays in language acquisition. It can also lead to marital conflicts, stressful family interactions and psychiatric disability leading to potential loss of income, and increase medical care costs. Like major depressive disorders the treatment of paternal postnatal depression may require psychopharmacological treatment typically with selective serotonin reuptake inhibitors or serotonin norepinephrine reuptake inhibitors. The purpose of this report is to increase clinicians awareness in recognizing and treating paternal postnatal depression as illustrated in a case of a 30 year-old new father who developed paternal postnatal depression and his progress in response to treatment with the first-of-class serotonin partial agonist reuptake inhibitor antidepressant vilazodone which basic pharmacology is summarized.

show abstract

Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive Disorder

Cited by 134 publications

References 0 publications

Antidepressant-Induced Sexual Side Effects: Incidence, Assessment, Clinical Implications, and Management

Antidepressant-Induced Sexual Side Effects: Incidence, Assessment, Clinical Implications, and Management

Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor

Vilazodone for the Treatment of Paternal Post Natal Depression

Contact Info

Product

Resources

About